Validation of anti-aging drugs by treating age-related diseases

被引：122

作者：

Blagosklonny, Mikhail V. ^{[1
]}

机构：

[1] Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA

来源：

AGING-US | 2009年 / 1卷 / 03期

关键词：

Anti-aging drugs; diseases; cancer; atherosclerosis; resveratrol; rapamycin; metformin; SMALL-MOLECULE ACTIVATORS; AKT/PROTEIN KINASE-B; EXTENDS LIFE-SPAN; P70; S6; KINASE; CARDIAC-HYPERTROPHY; CALORIE RESTRICTION; MAMMALIAN TARGET; ALZHEIMERS-DISEASE; REDUCED INCIDENCE; KAPOSIS-SARCOMA;

D O I：

10.18632/aging.100034

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend-life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular-degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could bevalidated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

引用

页码：281 / 288

页数：8

共 107 条

[11] Aging, stem cells, and mammalian target of rapamycin: A prospect of pharmacologic rejuvenation of aging stem cells [J].

Blagosklonny, Mikhail V. .

REJUVENATION RESEARCH, 2008, 11 (04) :801-808

[12] An anti-aging drug today: from senescence-promoting genes to anti-aging pill [J].

Blagosklonny, Mikhail V. .

DRUG DISCOVERY TODAY, 2007, 12 (5-6) :218-224

[13] Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy [J].

Bonegio, RGB ;

Fuhro, R ;

Wang, ZY ;

Valeri, CR ;

Andry, C ;

Salant, DJ ;

Lieberthal, W .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2063-2072

[14] Medical consequences of obesity [J].

Bray, GA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2583-2589

[15]

BRITO PM, 2008, ATHEROSCLER IN PRESS

[16] Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth [J].

Buzzai, Monica ;

Jones, Russell G. ;

Amaravadi, Ravi K. ;

Lum, Julian J. ;

DeBerardinis, Ralph J. ;

Zhao, Fangping ;

Viollet, Benoit ;

Thompson, Craig B. .

CANCER RESEARCH, 2007, 67 (14) :6745-6752

[17] Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation [J].

Campistol, Josep M. ;

Eris, Josette ;

Oberbauer, Rainer ;

Friend, Peter ;

Hutchison, Brian ;

Morales, Jose M. ;

Claesson, Kerstin ;

Stallone, Giovanni ;

Russ, Graeme ;

Rostaing, Lionel ;

Kreis, Henri ;

Burke, James T. ;

Brault, Yves ;

Scarola, Joseph A. ;

Neylan, John F. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (02) :581-589

[18] trans-3,4,5′-trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells [J].

Cao, ZX ;

Fang, J ;

Xia, C ;

Shi, XL ;

Jiang, BH .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :5253-5263

[19]

CARLSON RP, 1993, J PHARMACOL EXP THER, V266, P1125

[20] Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt [J].

Chan, Anita Y. M. ;

Dolinsky, Vernon W. ;

Soltys, Carrie-Lynn M. ;

Viollet, Benoit ;

Baksh, Shairaz ;

Light, Peter E. ;

Dyck, Jason R. B. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (35) :24194-24201

← 1 2 3 4 5 6 7 8 9 10 →